Fineline Cube

Follow:
14433 Articles
XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases
CompanyDeals

XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases

Sino Biopharm's LM-302 Shows Promising Results in Phase III Trials for Gastric Cancer
CompanyDrug

Sino Biopharm’s LM-302 Shows Promising Results in Phase III Trials for Gastric Cancer

GoodRx and Novo Nordisk Introduce $499 Monthly Pricing for Semaglutide Pens
CompanyDeals

GoodRx and Novo Nordisk Introduce $499 Monthly Pricing for Semaglutide Pens

InnoCare Pharma's Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1
Company

InnoCare Pharma’s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1

hina's Zelgen Secures FDA IND Approval for Triple-Targeted Cancer Drug ZGGS34
CompanyDrug

China’s Zelgen Secures FDA IND Approval for Triple-Targeted Cancer Drug ZGGS34

Hansoh's Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025
Company

Hansoh’s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025

Sichuan Kelun-Biotech Reports H1 Revenue Drop, Advances Key Drug Commercialization
Company

Sichuan Kelun-Biotech Reports H1 Revenue Drop, Advances Key Drug Commercialization

WuXi Biologics Reports 16.1% Revenue Growth in H1 2025, Launches WuXiHigh 2.0 Platform
Company

WuXi Biologics Reports 16.1% Revenue Growth in H1 2025, Launches WuXiHigh 2.0 Platform

RemeGen's RC148 Granted Breakthrough Therapy Designation for NSCLC Treatment
CompanyDrug

RemeGen’s RC148 Granted Breakthrough Therapy Designation for NSCLC Treatment

Shandong Lukang's CIGB-814 Starts Phase 1 Trial for Rheumatoid Arthritis Treatment
CompanyDrug

Shandong Lukang’s CIGB-814 Starts Phase 1 Trial for Rheumatoid Arthritis Treatment

HutchMed Completes Patient Enrollment for Orpathys and Tagrisso Combination Study
CompanyDrug

HutchMed Completes Patient Enrollment for Orpathys and Tagrisso Combination Study

Sino Biopharmaceutical Reports 10.7% Revenue Growth and 140.2% Profit Surge in H1 2025
Company

Sino Biopharmaceutical Reports 10.7% Revenue Growth and 140.2% Profit Surge in H1 2025